The Vanguard Group, Inc. recently announced the acquisition of new stake in Recursion Pharmaceuticals Inc (NASDAQ:RXRX). The institutional investor has increased its shareholding in the Healthcare company by 38.41% to 15.27 million shares with purchase of 4.24 million shares. This fresh investment now brings its stake to 7.33% valued currently at $104.6 million. In addition, SSgA Funds Management, Inc. raised its holdings by 6.06 million to 11.76 million shares. And Fidelity Management & Research Co has lifted its position by 133.51% or 6.09 million shares – to 10.64 million shares.
With over 10.64 million Recursion Pharmaceuticals Inc (RXRX) shares trading Friday and a closing price of $11.93 on the day, the dollar volume was approximately $126.93 million. The shares have shown a positive half year performance of 73.91% and its price on 01/05/24 gained nearly 7.38%. Currently, there are 183.21M common shares owned by the public and among those 151.83M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 176 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 80 of these insider trades were purchases, accounting for 2,509,056 shares. Insider sales of the common stock occurred on 96 occasions, with total insider shares sold totaling 1,821,052 shares.
The top 3 mutual fund holders in Recursion Pharmaceuticals Inc are Scottish Mortgage Investment Trus, SPDR S&P Biotech ETF, and ARK Genomic Revolution ETF. Scottish Mortgage Investment Trus owns 16.03 million shares of the company’s stock, all valued at over $109.8 million. SPDR S&P Biotech ETF bought 45240.0 shares to see its total holdings expand to 9.74 million shares valued at over $66.75 million and representing 4.68% of the shares outstanding. ARK Genomic Revolution ETF now owns shares totaling to 4.13% of the shares outstanding.
Shares of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened at $10.93, down -$0.18 from a prior closing price of $11.11. However, the script later moved the day high at 11.99, up 7.38%. The company’s stock has a 5-day price change of 12.44% and 67.79% over the past three months. RXRX shares are trading 20.99% year to date (YTD), with the 12-month market performance up to 52.56% higher. It has a 12-month low price of $4.54 and touched a high of $16.75 over the same period. RXRX has an average intraday trading volume of 4.28 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 27.69%, 59.62%, and 48.84% respectively.
Institutional ownership of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares accounts for 61.83% of the company’s 183.21M shares outstanding. Mutual fund holders own 22.60%, while other institutional holders and individual stakeholders account for 46.72% and 17.42% respectively.
It has a market capitalization of $2.58B and a beta (3y monthly) value of 0.59. The earnings-per-share (ttm) stands at -$1.47. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.21% over the week and 8.40% over the month.
Analysts forecast that Recursion Pharmaceuticals Inc (RXRX) will achieve an EPS of -$0.45 for the current quarter, -$0.44 for the next quarter and -$1.9 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.53 while analysts give the company a high EPS estimate of -$0.3. Comparatively, EPS for the current quarter was -$0.31 a year ago. Earnings per share for the fiscal year are expected to decrease by -21.53%, and -14.95% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Recursion Pharmaceuticals Inc (RXRX) as a “Moderate Buy” at a consensus score of 2.33. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 4 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the RXRX, a number of firms have released research notes about the stock. Morgan Stanley stated their Equal-Weight rating for the stock in a research note on May 22, 2023, with the firm’s price target at $8.
